Outcomes and Therapeutic Management of Bladder Cancer

Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invas...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Materialtyp: Online
Språk:engelska
Utgiven: MDPI - Multidisciplinary Digital Publishing Institute 2021
Ämnen:
Länkar:ONIX_20210501_9783039369348_825
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!
_version_ 1869516070951321600
collection Directory of Open Access Books
description Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.
format Online
id doab-20.500.12854ir-69079
institution Directory of Open Access Books
language eng
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-690792024-03-30T23:21:50Z Outcomes and Therapeutic Management of Bladder Cancer Moschini, Marco bladder cancer robotic-assisted open radical cystectomy survival propensity score age urothelial carcinoma outcome anesthesia recovery periods cognitive impairment gamma-cyclodextrins neuromuscular blockade robotic radical cystectomy glycogen clear-cell adenocarcinoma urinary bladder SEER program database female intracorporeal neobladder outcomes robotic sex-sparing methylation biomarkers FOXA1 GATA3 KRT20 molecular markers mRNA muscle-invasive bladder cancer PCR human epidermal growth factor receptor 2 indoleamine 2,3-dioxygenase programmed death ligand-1 immunotherapy nodal disease pN1 neoadjuvant adjuvant chemotherapy n/a thema EDItEUR::M Medicine and Nursing Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease. 2021-05-01T15:40:39Z 2021-05-01T15:40:39Z 2020 book ONIX_20210501_9783039369348_825 9783039369348 9783039369355 https://directory.doabooks.org/handle/20.500.12854/69079 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/2848 https://mdpi.com/books/pdfview/book/2848 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03936-935-5 10.3390/books978-3-03936-935-5 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783039369348 9783039369355 120 Basel, Switzerland open access
spellingShingle bladder cancer
robotic-assisted
open
radical cystectomy
survival
propensity score
age
urothelial carcinoma
outcome
anesthesia recovery periods
cognitive impairment
gamma-cyclodextrins
neuromuscular blockade
robotic radical cystectomy
glycogen
clear-cell adenocarcinoma
urinary bladder
SEER program database
female
intracorporeal neobladder
outcomes
robotic
sex-sparing
methylation
biomarkers
FOXA1
GATA3
KRT20
molecular markers
mRNA
muscle-invasive bladder cancer
PCR
human epidermal growth factor receptor 2
indoleamine 2,3-dioxygenase
programmed death ligand-1
immunotherapy
nodal disease
pN1
neoadjuvant
adjuvant
chemotherapy
n/a
thema EDItEUR::M Medicine and Nursing
Outcomes and Therapeutic Management of Bladder Cancer
title Outcomes and Therapeutic Management of Bladder Cancer
title_full Outcomes and Therapeutic Management of Bladder Cancer
title_fullStr Outcomes and Therapeutic Management of Bladder Cancer
title_full_unstemmed Outcomes and Therapeutic Management of Bladder Cancer
title_short Outcomes and Therapeutic Management of Bladder Cancer
title_sort outcomes and therapeutic management of bladder cancer
topic bladder cancer
robotic-assisted
open
radical cystectomy
survival
propensity score
age
urothelial carcinoma
outcome
anesthesia recovery periods
cognitive impairment
gamma-cyclodextrins
neuromuscular blockade
robotic radical cystectomy
glycogen
clear-cell adenocarcinoma
urinary bladder
SEER program database
female
intracorporeal neobladder
outcomes
robotic
sex-sparing
methylation
biomarkers
FOXA1
GATA3
KRT20
molecular markers
mRNA
muscle-invasive bladder cancer
PCR
human epidermal growth factor receptor 2
indoleamine 2,3-dioxygenase
programmed death ligand-1
immunotherapy
nodal disease
pN1
neoadjuvant
adjuvant
chemotherapy
n/a
thema EDItEUR::M Medicine and Nursing
topic_facet bladder cancer
robotic-assisted
open
radical cystectomy
survival
propensity score
age
urothelial carcinoma
outcome
anesthesia recovery periods
cognitive impairment
gamma-cyclodextrins
neuromuscular blockade
robotic radical cystectomy
glycogen
clear-cell adenocarcinoma
urinary bladder
SEER program database
female
intracorporeal neobladder
outcomes
robotic
sex-sparing
methylation
biomarkers
FOXA1
GATA3
KRT20
molecular markers
mRNA
muscle-invasive bladder cancer
PCR
human epidermal growth factor receptor 2
indoleamine 2,3-dioxygenase
programmed death ligand-1
immunotherapy
nodal disease
pN1
neoadjuvant
adjuvant
chemotherapy
n/a
thema EDItEUR::M Medicine and Nursing
url ONIX_20210501_9783039369348_825